Conroe is tops in Texas and No. 3 in the nation's list of boomtowns. Photo courtesy of Visit Houston

The Houston suburb of Conroe has come a long way since Civil War veteran Isaac Conroe planted roots there in October 1881 with the purchase of a tract of land and the establishment of a sawmill.

Fast forward 140 years, and Conroe now reigns as the leading boomtown in Texas. On November 2, personal finance website SmartAsset released a study ranking Conroe as the No. 1 boomtown in the state. Even more impressive: The city ties with Meridian, Idaho, for the No. 3 spot among the nation's top boomtowns. The No. 1 city overall is Murfreesboro, Tennessee, a suburb of Nashville.

Conroe did not show up among the country's top 50 boomtowns in SmartAsset's 2019 study.

SmartAsset evaluated data for 500 of the largest U.S. cities to come up with its list of the top boomtowns. It looked at growth factors for each city such as five-year population change, average yearly growth in economic output (GDP), five-year change in number of businesses, five-year growth in housing, and August 2021 unemployment rate.

Among the 500 cities, Conroe ranks fifth for the five-year population change (26.03 percent) and fourth for the five-year growth rate in housing (39.69 percent). On SmartAsset's 100-point boomtown scale, Conroe earns a score of 97.59.

As of April 2020, Conroe was home to nearly 90,000 people, according to the U.S. Census Bureau.

"Population growth in Conroe is not slowing. The increase continues to be steady. Conroe's median age and educational attainment [are] ideal for businesses looking to locate here," Danielle Scheiner, executive director of the Conroe Economic Development Council, said in April.

Conroe is the only city in the Houston area to make the top 50 on SmartAsset's boomtown list. However, five other Texas cities did break into the top 50:

  • New Braunfels (San Antonio metro area), tied for No. 14 with Concord, North Carolina. Boomtown score: 89.83. New Braunfels appeared at No. 6 in SmartAsset's 2019 boomtown study.
  • Austin, No. 17. Boomtown score: 89.52. Austin appeared at No. 12 in SmartAsset's 2019 boomtown study.
  • Round Rock (Austin metro area), tied for No. 25 with Charleston, South Carolina. Boomtown score: 86.98. Round Rock appeared at No. 10 in SmartAsset's 2019 study.
  • Denton (Dallas-Fort Worth metro area), No. 36. Boomtown score: 83.87. Denton appeared at No. 2 in SmartAsset's 2019 boomtown study.
  • McKinney (Dallas-Fort Worth metro area), No. 39. Boomtown score: 83.59. McKinney appeared at No. 14 in SmartAsset's 2019 boomtown study.

Four Texas cities dropped out of the boomtown ranking from 2019 to 2021: Frisco, which ranked 13th two years ago; College Station, ranked 16th; Flower Mound, ranked 24th; and Allen, ranked 37th.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”